Skip to content
    BTSG
    Earnings call· Mar 2026(Q1 FY26)

    BrightSpring Health Services Q1 FY26 earnings call BTSG

    May 1, 2026 Source

    Executive summary

    BrightSpring Health Services Q1 FY26 — Strong Growth Across Pharmacy and Provider Segments

    BrightSpring delivered strong Q1 FY26 results, driven by broad-based growth in both pharmacy and provider segments and significant margin expansion. The company successfully integrated recent home health acquisitions and reduced leverage post-divestiture, positioning it for continued strategic investments and operational efficiencies despite expected IRA headwinds in Home & Community Pharmacy.

    Highlights

    5
    • Total company revenue grew 26% year-over-year to $3.6 billion.

    • Adjusted EBITDA grew 45% year-over-year to $190 million, with margin improvement of 70 basis points to 5.3%.

    • Pharmacy Solutions revenue grew 25% to $3.2 billion, with specialty and infusion revenue up 36% to $2.6 billion.

    • Provider Services revenue grew 28% to $442 million, with Home Healthcare up 49% to $266 million.

    • Leverage reduced to 2.27x as of March 31, 2026, from 2.99x as of December 31, 2025, post Community Living divestiture.

    Concerns

    3
    • Home & Community Pharmacy revenue declined 9% year-over-year due to an approximately $50 million impact from the IRA.

    • Expected full-year 2026 Home & Community Pharmacy revenue impact of approximately $175 million from the IRA.

    • Approximately $100 million in cash taxes related to the Community Living divestiture is expected to be paid in Q2 2026.

    Guidance & targets

    12
    CategoryTargetConfidence
    Total revenue
    $14.725B to $15.225B
    high materiality
    High
    Pharmacy Solutions revenue
    $12.85B to $13.3B
    medium materiality
    High
    Provider Services revenue
    $1.875B to $1.935B
    medium materiality
    High
    Total adjusted EBITDA
    $795M to $825M
    high materiality
    High
    Annual operating cash flow
    approximately $500M
    medium materiality
    High
    Adjusted EBITDA contribution from Amedisys and LHC assets
    approximately $30M
    medium materiality
    High
    Quarterly interest expense
    approximately $35M
    low materiality
    High
    Home & Community Pharmacy revenue impact from IRA
    approximately $175M
    medium materiality
    High
    Specialty and Infusion IRA impact
    about $181M
    medium materiality
    High
    Brand to generic conversions impact
    about $250M
    medium materiality
    High
    Adjusted EBITDA margin
    5.2% to 5.6%
    medium materiality
    High
    Mitigated headwind on EBITDA line
    $15M
    low materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Pharmacy Solutions
    Strong performance driven by specialty and infusion, LDD wins, and generic utilization. Home & Community Pharmacy revenue impacted by IRA and customer exits, but profitability was up year-over-year excluding IRA.
    Specialty and Infusion revenue: $2.6B (+36% YoY)Home & Community Pharmacy revenue: $527M (-9% YoY)Specialty and Infusion script growth: ~30% YoYSpecialty script growth: >30% YoYInfusion script growth: mid-teens YoYHome & Community Pharmacy modest trip growth (ex-uneconomic customers): mid-single digitsLDDs added: 4 exclusive and UltraARTotal LDDs: 153Dispensing accuracy: 99.99%Order completeness: 99%On-time delivery: 96%Infusion patient satisfaction: 94%Infusion discharges due to completion of therapy: 97%Specialty pharmacy medication possession ratio: 92.1%Specialty pharmacy time to first fill: 4.6 days
    $3.2B25%$169M Adjusted EBITDA (5.3% margin)
    Provider Services
    Growth driven by Home Healthcare, benefiting from census growth, de novo expansion, and successful integration of acquired branches. Rehab and Personal Care also showed consistent growth and high patient satisfaction.
    Home Healthcare revenue: $266M (+49% YoY)Home Healthcare acquired assets revenue contribution: $79MHome Healthcare acquired assets adjusted EBITDA contribution: $9MRehab revenue: $75M (+7% YoY)Personal Care revenue: $102M (+4% YoY)Home Health branches 4 stars or greater: >91%Home Health timely initiation of care: >99%Hospice quality measures: well above national averageHospice CAPS overall rating: 87%Rehab patient satisfaction (outpatient): 98%Rehab patient satisfaction (Home & Community): 97%Personal Care client satisfaction: 4.6 out of 5
    $442M28%$66M Adjusted EBITDA (14.9% margin)

    Operational metrics

    9
    Net debt outstanding
    ~$1.7B
    as of March 31, 2026

    Following Community Living divestiture.

    Community Living divestiture net cash proceeds
    $811M
    Q1 FY26

    Proceeds from the sale of Community Living to Savita.

    Community Living divestiture gross cash consideration
    $835M
    Q1 FY26

    Gross cash consideration for the sale of Community Living.

    Cash taxes expected from Community Living proceeds
    $100M
    Q2 FY26

    Expected to be paid in Q2 2026.

    Internal AI team headcount
    >20
    Current

    Investment in AI and technology systems.

    Process improvement projects completed
    >700
    last 5+ years

    Part of continuous improvement efforts.

    Process improvement savings generated
    9 figures
    last 5+ years

    Savings generated from process improvement initiatives, reinvested into people, IT, and technology systems.

    Hub programs
    31
    Current

    Part of fee-for-service business.

    Fee-for-service growth
    40-50%YoY
    Q1 FY26

    Growth in hub programs and service agreements.

    Industry KPIs

    3
    MetricValueDetails
    Pharmacy scripts specialty~30%%
    Segment revenue operating income$3.2BUSD
    Adjusted EPS EBITDA leverage guidance$0.39USD/share

    Deals & partnerships

    2
    SavitaSale of Community Living business$835M gross cash consideration

    The sale of the Community Living business resulted in significant cash proceeds used to strengthen the balance sheet.

    Amedisys and LHCAcquisition of home health branches

    Integration of acquired home health branches is progressing well, contributing significantly to Provider Services growth.

    Risks & headwinds

    3
    IRA impact on Home & Community Pharmacy revenueQ1 FY26, full year FY26

    $50M in Q1 FY26; expected $175M for full year 2026

    Mitigation: Exiting uneconomic customers, operational efficiencies, procurement initiatives.

    Cash taxes related to Community Living divestitureQ2 FY26

    $100M

    Mitigation: Factored into pro forma leverage calculations.

    Biosimilar risk exposureCurrent

    Not much exposure

    Mitigation: Product portfolio focus on oral solids and infusibles, rather than injectables; no significant concentration in areas with biosimilar risk.

    What to watch in Q2 FY26

    5

    Home & Community Pharmacy revenue impact from IRA

    Q2 FY26
    Current$50M in Q1 FY26
    TargetTracking towards expected $45M impact for Q2 FY26

    Why it matters

    This is a significant headwind, and management's ability to manage it through operational efficiencies and customer exits is key to segment profitability.

    We expect to see a revenue impact from the IRA of approximately $45 million for each of the remaining quarters of 2026, totaling our Home and Community Pharmacy revenue impact of approximately $175 million for the full year of 2026.

    Q&A highlights

    7

    Can you discuss the growth initiatives in infusion, particularly the chronic portfolio expansion, growth rates, and focused drug classes?

    The company saw double-digit growth in both acute and chronic specialty infusion. They launched a concierge program for IVIG and are building out similar programs for targeted therapies. Growth in Onco360 and CareMed businesses is driven by LDDs, new accounts, and non-oncology therapeutic areas.

    we did see double-digit growth on both the acute side and the chronic specialty side. So I think as we've mentioned before, we've been underweight on chronic specialty. So we think that's an opportunity.

    asked by Ann Hynes · answered by Jon Rousseau

    3 min read6 chapters

    Detailed Narrative

    01

    Strategic Focus and Market Trends

    BrightSpring emphasizes its leadership in Home & Community health services, serving complex patients with high-quality, lower-cost care. The company is positioned to capitalize on key healthcare trends, including home-based care and value-based models, leveraging its scale and disciplined operating model for sustainable growth and operational efficiencies. Management highlighted the company's focus on patient and provider outcomes, continuous improvement, and best practice sharing to expand impact and provide comparatively lower cost services for complex patients.

    02

    Pharmacy Solutions Performance

    The Pharmacy Solutions segment demonstrated healthy growth, particularly in specialty and infusion, driven by strong script growth, new LDD wins, and generic utilization. Specialty and infusion revenue grew 36% to $2.6 billion. The company added 4 exclusive and UltraAR LDDs, bringing the total to 153. Investments in automation across the national pharmacy footprint and geographic expansion, especially in infusion, are key drivers. The Home & Community Pharmacy segment faced an expected 9% revenue decline due to IRA impacts and customer exits but showed underlying operational strength, with profitability up year-over-year excluding IRA.

    03

    Provider Services Growth

    The Provider Services segment saw significant growth, with Home Healthcare revenue growing 49% to $266 million. This was driven by strong census growth, de novo expansion, preferred MA contracts, and successful integration of acquired Amedisys and LHC branches, which contributed $79 million in revenue and $9 million in adjusted EBITDA in Q1. Rehab revenue grew 7% to $75 million, and Personal Care revenue grew 4% to $102 million, both showing consistent growth and high patient satisfaction scores.

    04

    Operational Efficiencies and AI Investment

    The company continues to prioritize operational efficiencies and process improvements, attributing significant savings to these initiatives. Investments in AI and technology are streamlining workflows, such as reducing infusion order intake time from hours to seconds. Over 700 process improvement projects have been completed in the last five years, generating nine figures of savings, which are reinvested into people, IT, and technology systems. The internal AI team now comprises over 20 people, focusing on leveraging data and analytics for proactive care approaches.

    05

    Balance Sheet Strength and Capital Allocation

    Following the divestiture of the Community Living business to Savita for $835 million gross cash consideration, BrightSpring significantly strengthened its balance sheet. Net cash proceeds before tax of $811 million were used to reduce leverage to 2.27x as of March 31, 2026, down from 2.99x at year-end 2025. The company plans to evaluate options for its existing term loan and capital structure, maintaining a disciplined approach to M&A with a focus on strategic tuck-ins and geographic expansion.

    06

    Quality Outcomes and Patient Satisfaction

    Management highlighted strong quality metrics across all service lines. Over 91% of Home Health branches are 4 stars or greater, with timely initiation of care exceeding 99%. Hospice quality measures are well above the national average, with a CAPS overall rating of 87%. Patient satisfaction scores are 98% for outpatient rehab and 97% for Home & Community rehab. Pharmacy services reported 99.99% dispensing accuracy, 99% order completeness, and 96% on-time delivery, with specialty pharmacy demonstrating a 92.1% medication possession ratio.

    AI-generated summary of the company’s earnings call. Not investment advice.